Theravance Biopharma(Delisted)

Recent news

• Company notice
  Theravance Biopharma: Theravance Biopharma, Inc. - Partial Self Tender Offer Option Symbol: TBPH
  OCC · 2022/10/4
• Rating change
  B. Riley Securities Maintains Theravance Biopharma(TBPH.US) With Hold Rating, Raises Target Price to $17
  Market Newswire · 2026/4/7
• Company notice
  Theravance Biopharma(Delisted): Theravance Biopharma, Inc. - Cash Settlement/Acceleration of Expirations Option Symbol: TBPH
  OCC · 2026/9/24
• Rating change
  TD Cowen Maintains Theravance Biopharma(TBPH.US) With Hold Rating, Raises Target Price to $15
  Market Newswire · 2026/3/23
• Rating change
  BTIG Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Maintains Target Price $21
  Market Newswire · 2026/5/8
• Rating change
  B. Riley Securities Downgrades Theravance Biopharma(TBPH.US) to Hold Rating, Cuts Target Price to $14
  Market Newswire · 2026/3/4
• Company notice
  Theravance Biopharma: Theravance Biopharma, Inc. - Anticipated Cash Settlement Option Symbol: TBPH
  OCC · 2026/8/29
• Rating change
  TD Cowen Maintains Theravance Biopharma(TBPH.US) With Hold Rating, Maintains Target Price $15
  Market Newswire · 2026/3/23
• Rating change
  JonesTrading Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Raises Target Price to $18
  Market Newswire · 2026/3/26
• Rating change
  JonesTrading Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Raises Target Price to $19
  Market Newswire · 2026/5/28
• Rating change
  Analysts' Opinions Are Mixed on These Healthcare Stocks: Rocket Pharmaceuticals (RCKT), Fractyl Health, Inc. (GUTS) and Theravance Biopharma (TBPH)
  TipRanks · 2026/8/11
• BTIG Downgrades Theravance Biopharma(TBPH.US) to Hold Rating
  Market Newswire · 2026/6/29
• H.C. Wainwright Downgrades Theravance Biopharma(TBPH.US) to Hold Rating, Raises Target Price to $17
  Market Newswire · 2026/7/7
• Company notice
  Theravance Biopharma(Delisted): Theravance Biopharma, Inc.- Broker-To-Broker Settlement/Exercise Considerations Option Symbol: TBPH
  OCC · 2026/9/24
• Theravance Biopharma(TBPH.US) 10% Shareholder Sells US$5.79 Million in Common Stock
  Market Newswire · 2026/7/2
• Rating change
  JonesTrading Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Cuts Target Price to $17
  Market Newswire · 2026/3/5
• Rating change
  H.C. Wainwright Maintains Theravance Biopharma(TBPH.US) With Buy Rating, Cuts Target Price to $15
  Market Newswire · 2026/3/5
• H.C. Wainwright Maintains Theravance Biopharma(TBPH.US) With Hold Rating, Maintains Target Price $17
  Market Newswire · 2026/8/11
• Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Theravance Biopharma (TBPH)
  TipRanks · 2026/6/29
• Rating change
  Oppenheimer Downgrades Theravance Biopharma(TBPH.US) to Hold Rating, Cuts Target Price to $13.67
  Market Newswire · 2026/3/6

Headlines are aggregated automatically and are not independently verified or edited by our team.